CASI is a NASDAQ-listed biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products.
For questions about Investor Relations, please contact: USA. Rui Zhang. Phone: +1-240-864-2643. Email: ir@casipharmaceuticals.com. China. William Chen.
CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States ...
Missing: investor relations
View the Most Current Investor Presentation Here. Contact Information. George Price Senior Vice President of Investor Relations (703) 841-7818 ir@caci.com.
Missing: casi | Show results with:casi
Mar 28, 2024 · CASI is currently involved in arbitration proceedings against Juventas in relation to Juventas's purported termination of the CNCT-19 Agreements ...
The Company holds 80 % of the equity interests in CASI Wuxi and will invest, over time, $ 80 million in CASI Wuxi. The Company's investment will consist of (i) ...
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports ( ...
This information can be used by investors to verify and understand the financial position of the company. Many, but not all SEC filings are available in the ...
... investor relations and facilities. General and administrative expenses were $5.5 million and $10.8 million, respectively, for the three and six months ended ...
Mar 5, 2024 · Cecilia Hofvander, Senior Director Investor Relations Phone: +46 (0)46 286 85 50. Email: cecilia.hofvander@bioinvent.com. BioInvent ...
Diversify your portfolio by investing in real estate, art, legal and more asset classes. Invest in asset classes traditionally dominated by hedge funds...